The Manufacturers Life Insurance Company Makes New Investment in CONMED Corporation $CNMD

Posted by Stanley Muller on Sep 8th, 2026

The Manufacturers Life Insurance Company bought a new stake in shares of CONMED Corporation (NYSE:CNMD – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 12,609 shares of the company’s stock, valued at approximately $413,000.

A number of other hedge funds also recently modified their holdings of CNMD. Paradigm Capital Management Inc. NY acquired a new stake in shares of CONMED in the second quarter worth $17,617,000. Algert Global LLC raised its position in CONMED by 56.3% during the second quarter. Algert Global LLC now owns 131,293 shares of the company’s stock valued at $4,297,000 after buying an additional 47,293 shares during the period. Sanctuary Advisors LLC purchased a new stake in CONMED in the 2nd quarter worth about $238,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in CONMED in the 2nd quarter worth about $716,000. Finally, Ieq Capital LLC acquired a new stake in CONMED during the 2nd quarter worth about $362,000.

CONMED Stock Down 0.7%

Shares of CONMED stock opened at $48.97 on Tuesday. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of 26.47, a P/E/G ratio of 2.25 and a beta of 0.90. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.48 and a quick ratio of 0.69. CONMED Corporation has a 52-week low of $31.44 and a 52-week high of $56.63. The stock has a 50-day simple moving average of $45.25 and a 200-day simple moving average of $40.11.

CONMED (NYSE:CNMD – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.11 by $0.27. The business had revenue of $343.49 million during the quarter, compared to analysts’ expectations of $337.60 million. CONMED had a return on equity of 14.31% and a net margin of 4.12%.The firm’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 EPS. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, equities research analysts expect that CONMED Corporation will post 4.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Piper Sandler reiterated a “neutral” rating and issued a $45.00 target price (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. BMO Capital Markets began coverage on shares of CONMED in a report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price target for the company. Wall Street Zen raised shares of CONMED from a “hold” rating to a “buy” rating in a research report on Monday, July 20th. Zacks Research upgraded shares of CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of CONMED from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, CONMED has an average rating of “Reduce” and an average target price of $41.40.

View Our Latest Stock Report on CNMD

CONMED Company Profile

(Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.